Skip to main content
DYAI
NASDAQ Life Sciences

Dyadic Q2 Results Show Commercial Traction with First Product Sales and 80% Yield Jump

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1
Mkt Cap
$38.261M
52W Low
$0.655
52W High
$1.6
52W Position info
53% above low
Off High info
38% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

DYAI sits 53% above its 52-week low of $0.655.

Summary

Dyadic reported Q2 2026 results with accelerating commercial momentum. The company shipped six recombinant protein products and generated initial pilot sales for cultivated-meat applications. An 80% productivity increase in recombinant human transferrin strengthens manufacturing economics. Multiple partnerships advanced: Proliant began commercializing Albufree DX, Fermbox Bio scaled orders, and Inzymes confirmed initial sales of bovine chymosin. The C1 platform continues to gain validation through Gates Foundation-funded RSV and malaria programs and rapid pandemic response capabilities. This follows the Nasdaq compliance resolution in July and builds on the Q1 revenue surge, signaling a shift toward recurring commercial revenue. The earnings call at 5:00 pm ET may provide financial specifics and guidance.

Updates

  1. · SEC 8-K — Management issued a going concern warning as cash dwindled to $4.79 million.

At the time of this announcement, DYAI was trading at $1.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $38.3M. The 52-week trading range was $0.65 to $1.60. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

DYAI - Latest Insights

DYAI
Nov 13, 2026, 4:00 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.327
Real-time Price: $0.350 info
Change: +$0.023 (+7%) info
Market Cap: $13.101M info
DYAI
Nov 12, 2026, 4:05 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.3501
Real-time Price: $0.350 info
Change: -$0.0001 (-0.03%) info
Market Cap: $13.101M info
DYAI
Sep 25, 2026, 5:27 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.4198
Real-time Price: $0.350 info
Change: -$0.0698 (-17%) info
Market Cap: $13.101M info
DYAI
Aug 17, 2026, 7:27 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.710
Real-time Price: $0.350 info
Change: -$0.360 (-51%) info
Market Cap: $13.101M info
DYAI
Aug 14, 2026, 9:17 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.7702
Real-time Price: $0.350 info
Change: -$0.4202 (-55%) info
Market Cap: $13.101M info